Receptor activator for nuclear factor-κB ligand signaling promotes progesterone-mediated estrogen-induced mammary carcinogenesis
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Estrogen and progesterone are known factors in the occurrence and progression of breast cancer, however, the specific pathway and role of progesterone remains unclear. Boopalan and fellow researchers studied the effect of progesterone on receptor activator for nuclear factor-κB ligand (RANKL), a known factor in mammary carcinogenesis in mice and *in vitro* models. They found that estrogen induces progesterone to activate RANKL through the mediator glioma-associated oncogene homolog 1, thus promoting carcinogenesis and further inhibiting apoptosis. This important study further underpins the molecular mechanisms behind the potentially dangerous role that progesterone may have in breast cancer.doi: 10.1111/cas.12571
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Gastrointestinal stromal tumor (GIST) is a common type of soft-tissue sarcoma but little is known about prognostic factors or what makes intestinal GIST so much more deadly than gastric GIST. In this study, Ichikawa and colleagues investigated surgically obtained specimens from both intestinal and gastric GISTs looking for a difference in gene expression. They found promyelocytic leukemia (*PML*), a known tumor suppressor gene, to be downregulated in intestinal GIST and, furthermore, that it proved to be an independent prognostic factor for recurrence-free survival. This significant research breaks ground for future prospective studies of this marker and opens up possibilities for learning how to alter the activity of *PML* to increase survival.doi: 10.1111/cas.12565

Therapeutic activity of glycoengineered anti-GM2 antibodies against malignant pleural mesothelioma
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Malignant pleural mesothelioma is a highly aggressive disease and there is often limited hope for cure. In this study, Li *et al*. examined ganglioside GM2 expression in cancer cell lines and clinical specimens of mesothelioma and found the majority of the tumors to be positive. They then used BIW-8962, an anti-GM2 antibody, to treat these tumors and discovered significant reductions in both tumor progression and occurrence.

Furthermore, they showed a reduction in the incidence of pleural effusions, a common consequence of mesothelioma. These results are exciting as they open the door to a possible immunotherapy to apply to this devastating disease.doi: 10.1111/cas.12575
